duction at the cost of curtailment of production of essential drugs falling under category I and II; and

(f) if so, what are the details thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The desired information is as under:

Name of the company	Date of Issue of show cause notice	Date of receipt of reply
1. M/s Burroughs Wellcome	March, 1984	September, 1984
2. M/s Glaxo Labs.	September, 1984	December, 1984
3. M/s Pfizer	December, 1984	January, 1985

(b) and (c) No final decision has yet been taken on the findings of the Technical Team, as a policy decision is required to be taken.

(d) The requisite information regarding M|s. Burroughs Wellcome and M|s. Glaxo has been furnished in reply to Rajya Sabha Unstarred Question No. 161 dated 18-11-1985. The prices charged by M|s. Pfizer Limited for Oxytetracycline and its salts and certain multivitamin formulations, are in accordance with the orders of the Delhi and Bombay High Court.

(e) and (f) No, Sir. Production of formulations is tailored to market demand.

Price Fixation of products of M|s. Abbott. Lab.

2194. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 187 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when M/s. Abbott Lab. filed material to Government in support of their claim for higher prices of formulations than the prices fixed by Government;

(b) when was the hearing given to Abbott;

(c) whether Government have taken a final decision;

(d) if so, what are the details thereof;

(e) what was the sales turn over of the formulations for which M/s. Abbott Lab. did not implement the fixed prices during the last three years, year-wise;

(f) what was the unintended profit made by the company due to non-implementation of prices from the date of fixation order till today; and

(g) what steps have been taken by Government to make these products available at fair prices to public?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) to (d) After M|s. Abbott submitted their representation, hearing was given to M/s. Abbott Laboratories in August, 1985 and action is already on to take a final decision in the matter.

(e) Sales turnover of formulations is not monitored.

(f) The Company is charging the prices as allowed by the Bombay High Court and as such there is no question of any unintended profit.

(g) The prices of these products are regulated in accordance with the Drug (Priees Control) Order, 1979.

Price of Listerin and Pyridium

2195. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 189 given in the Rajya Sabha on 18th November, 1985 and state:

(a) whether Government have fixed the prices of Listerin and Pyridium Tablets;

(b) if so, when and what price has been fixed for each;

(c) if not, what are the reasons for the delay when Government have already categorised these products under category III;

(d) since when the company has been overcharging and selling these products at their own prices;

(e) whether Government have worked out the amount overcharged by the company since 1976;

(f) if so, the amount worked out each year; and

(g) what steps have been taken to recover the overcharged amount and by when it will be recovered?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) and (b) The price of Listerin and Pyridium Tablets was not fixed under Drugs (Prices Control) Order, 1979. The company was found treating these formulations as price decontrolled under the said Order.

(c) to (g) When it came to Government notice that company is treating the two formulations as price decontrolled, notices were issued to the company. The company have represented against the notice issued to them in respect of Listerin recently and action is on on their representation. No representation on Pyridium Tablets has been received.

On the spot verification of unauthorised installation of lant etc., of drug companies

2196. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 188 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) whether the technical team had submitted its findings in respect of on-the-spot verification of unauthorised installation of plant and machinery of all the 13 companies;

(b) if so, when was each report submitted and what were their findings in regard to each verificaiton;

(c) in how many cases final decision has been taken along with name of each company and the details of final decision;

(d) what are the details of additions made in plant and machinery since 1978 year-wise along with the name of machinery, value and purpose of which it is being used in respect of units where final decision has been taken; and

(e) what were the records and basis on which the team gave its findings?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Yes, Sir.

(b) to (e) Details of submission of Reports are given in the Statement Annexed. *(See below)* Other details have been furnished in reply to Rajya Sabha Unstarred Questions No. 2272 dated 19-8-85 and No. 161 dated 18-11-1985.

Statement

Name of the Company	Date of submission of report
1. M/s Glaxo Laboratories India Limited .	(i) July, 1984 (Betamethasone) (ii) September, 1984 (Formulations)
2. M/s Burroughs Wellcome . . .	October, 1983
3. M/s Pfizer Limited	(i) July, 1984 (Oxytetracycline) (ii) September, 1984 (Formulations)
4. M/s Bayer India Ltd.	June, 1984
5. M/s S.G. Pharmaceuticals . . .	July, 1984